In this issue:
Leukaemia selection:
Allogeneic SCT in adults with Philadelphia-negative ALL
CLL outcomes after ibrutinib discontinuation
3-year follow-up of ibrutinib in CLL and SLL
Comorbidity and performance status in AML
Lymphoma selection:
Omission of dacarbazine/bleomycin from ABVD in HL
PET-directed therapy for earlystage HL
Noninvasive DLBCL monitoring with Ig-HTS
Bortezomib-based therapy for new MCL
DA-EPOCH-R in poor-prognosis large B-cell lymphoma
Please login below to download this issue (PDF)